Correlation between polymorphism of cytochrome P450 1A2 gene and antidepressant clinical efficacy of duloxetine
10.3760/cma.j.issn.1674-6554.2014.02.014
- VernacularTitle:细胞色素P450酶1A2基因多态性与度洛西汀抗抑郁临床疗效的关系
- Author:
Dongbo LIU
;
Shuying LI
;
He CUI
;
Yali WANG
;
Binhua ZHU
;
Fang CHEN
;
Huirong GUO
- Publication Type:Journal Article
- Keywords:
Cytochrome P450 1A2;
Polymorphism (Genetics);
Duloxetine;
Clinical efficacy
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2014;23(2):144-147
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between C734A and G-2964A polymorphism of cytochrome P450 1A2 gene and clinical efficacy of duloxetine.Methods 223 patients with depression were treated with duloxetine for six weeks.The clinical efficacy was evaluated with the Hamilton rating scale for depression (HAMD) ;single nucleotide polymorphism (SNP) at position C734A and G-2964A of CYP1A2 gene were identified with restriction fragment length polymorphism(RFLPs) ;then one-way ANOVA was adopted to analyze the relationship between SNP and clinical efficacy.Results (1) In 223 patients,the frequency of allele A at locus 734 was 63.64％,while that of allele A at locus-2964 was 26.82％.(2) 220 patient underwent the whole treating course.The conjoint analysis of two locuses indicated that the decreasing ratio of HAMD score of high-activity group,middle-activity group and low-activity after treatment was (56.05± 10.13) ％,(66.36± 8.66) ％ and (73.82± 7.10) ％ respectively,the differences obtained by pairwise comparison of the three groups were of statistical significance(P＜0.01).Conclusion There is close relationship between C734A and G-2964A polymorphism of CYP1A2 gene and clinical efficacy of duloxetine in the treatment for depression.
